CLDN18.2 CAR-T cells eliminate pancreatic cancer cells

Arovella’s unique and patent protected CLDN18.2 CAR has been demonstrated to induce effective killing of pancreatic cancer cells when incorporated into T cells in a proof-of-concept in vitro study.

• Arovella’s CLDN18.2 CAR performed equivalently to the leading CLDN18.2 CAR, and the anti-tumour activity of the CAR is anticipated to be superior in vivo when incorporated into Arovella’s iNKT cell platform.

• Arovella is proceeding to incorporate its CLDN18.2 CAR into iNKT cells, which will be followed up with in vivo pancreatic and gastric cancer studies in mice.

• Arovella is one of very few companies developing a CLDN18.2-targeting CAR-iNKT cell therapy.

MELBOURNE, AUSTRALIA 02 October 2025: Arovella Therapeutics Ltd (ASX: ALA) ACN 090 987 250 (Arovella or the Company) is pleased to announce that it has further confirmed the functionality of its novel claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor (CAR) by demonstrating that CLDN18.2 CAR-T cells robustly eliminate pancreatic cancer cells that express CLDN18.2. The study confirmed the potent activity of Arovella’s CLDN18.2 CAR against a pancreatic cancer cell line, with pancreatic cancer being one of the more aggressive, and low survival cancer types with limited treatment options. The study was performed at the University of North Carolina, under the guidance of Professor Gianpietro Dotti.

Learn more here.